Production Linked Incentive (PLI) Scheme for Pharmaceuticals
Ministry of Chemicals and Fertilizers · Central government
A central government scheme funding pharmaceutical goods and in-vitro diagnostic medical device makers with financial incentives on incremental sales to boost India's domestic manufacturing.
Closed. This scheme is not accepting applications. The details below describe the most recent cycle.
Key facts
- Subsidy amount
- ₹15,00,000 – ₹10,00,00,00,000
- Instrument
- Subsidy
- Deadline
- Not specified
- Disbursement
- Released against milestones
- Scheme duration
- 73 months
About this scheme
The Ministry of Chemicals and Fertilizers, through its Department of Pharmaceuticals, has introduced the Production Linked Incentive (PLI) Scheme for Pharmaceuticals. Its main aim is to strengthen India's pharmaceutical manufacturing base, encourage higher investment and output, and shift production towards higher-value goods such as advanced pharmaceutical products and in-vitro diagnostic medical devices. Incentives are linked to incremental sales over a defined base year, with the goal of positioning India as a leading player in the global pharmaceutical supply chain.
The Small Industries Development Bank of India (SIDBI) serves as the Project Management Agency (PMA) for the scheme. It handles applications and supports the disbursement of incentives through a dedicated online portal.
The scheme is intended to reinforce the domestic pharmaceutical ecosystem, support innovation, and lower dependence on imports for critical pharmaceutical ingredients and finished products.
Who can apply
- Eligible business forms
- Private limited company, Limited liability partnership, One person company, Partnership firm, Sole proprietorship
- Udyam registration
- Not specified
- MSME registration
- Not specified
- DPIIT startup recognition
- Not specified
- GST registration
- Not specified
- Revenue band
- From ₹5,00,000
- Where the business may be based
- Not restricted
- The applicant must be a manufacturer of pharmaceutical goods registered in India. - The applicant must manufacture eligible pharmaceutical products within the three defined categories. - The applicant must not claim incentives for the same product under any other PLI scheme. - **Group A:** Global Manufacturing Revenue of pharmaceutical goods or in-vitro Diagnostic Medical Devices of ₹5,000 crores or more in FY 2019-20, with a minimum cumulative investment of ₹1,000 crores over 5 years and a minimum eligible product turnover of ₹50 crores in FY 2022-23. - **Group B:** Global Manufacturing Revenue between ₹500 crores and ₹5,000 crores in FY 2019-20, with a minimum cumulative investment of ₹250 crores over 5 years and a minimum eligible product turnover of ₹10 crores in FY 2022-23. - **Group C:** Global Manufacturing Revenue below ₹500 crores in FY 2019-20, with a minimum cumulative investment of ₹50 crores over 5 years and a minimum eligible product turnover of ₹1 crore in FY 2022-23. - **Group C (MSME):** Must fall within the Micro, Small and Medium Enterprises (MSME) category under Group C, commit eligible investment over 5 years, and achieve a minimum eligible product turnover of ₹50 lakhs in FY 2022-23. - **Continuation:** To keep claiming incentives in subsequent years (FY 2023-24 onwards), applicants must achieve 7% growth in sales over the previous financial year.
How to apply
1. **Access the portal:** Go to the official online portal at https://pli-pharma.udyamimitra.in. 2. **Register and apply:** Create a registration on the portal, then complete the full application form, entering all required particulars on your Global Manufacturing Revenue, investment commitments and the specific pharmaceutical product categories in which your company operates. 3. **Pay the application fee:** Remit the non-refundable application fee as set out in the scheme guidelines. 4. **Await processing:** The Project Management Agency (SIDBI) will process the applications received and evaluate them under a predefined ranking methodology. This selection process is usually completed within 90 days of the application window closing. 5. **Receive approval:** Where an application is successful, the Project Management Agency will issue an official approval letter. 6. **Furnish guarantees:** Within two weeks of receiving the approval letter, submit a Bank Guarantee for the prescribed amount together with an Undertaking in favour of the Department of Pharmaceuticals. 7. **Claim incentives annually:** Each year, file your claims for incentive disbursement through the online portal, with all required supporting documents, within one month of the financial year closing.
How applications are assessed
The Project Management Agency (SIDBI) evaluates every application it receives. A pre-defined ranking methodology governs selection, and the factors it weighs include the applicant's Global Manufacturing Revenue, committed investments and proposed product categories. Results are usually communicated within 90 days of the application window closing.
Frequently asked questions
What is the primary goal of the PLI Scheme for Pharmaceuticals?
The scheme seeks to strengthen India's domestic manufacturing, draw in substantial investment and encourage diversification into high-value pharmaceutical products and in-vitro diagnostic medical devices, so that dependence on imports is reduced.
Who is eligible to apply for this PLI scheme?
Eligibility is open to Indian-registered manufacturers of pharmaceutical goods whose products fall within the scheme's three categories, and it further depends on global manufacturing revenue and committed investment, which place applicants in Group A, B or C under criteria specific to each group, with a sub-category for MSMEs within Group C.
How are the financial incentives calculated and paid out?
Incentives are a percentage (3% to 10%) of net incremental sales over a base year, paid across 6 years. Claims are filed online annually, with 75% of the approved amount released immediately and the remaining 25% on submission of final audited accounts.
What are the maximum incentives an applicant can receive?
Under the scheme, Group A companies can receive a maximum incentive of ₹10,000 crore, Group B companies ₹2,500 crore, and Group C companies ₹50 crore.
Is MSME registration required for this scheme?
MSMEs are not universally required to meet the standard thresholds, as Group C contains a separate eligibility sub-category for Micro, Small and Medium Enterprises; MSMEs that satisfy this group's criteria may apply under the relaxed thresholds.
What is the application process for the PLI Pharma Scheme?
Applications are made online through the Project Management Agency (SIDBI) portal, where applicants register, complete the form and pay a non-refundable fee; those selected must then submit a Bank Guarantee and an Undertaking, and annual incentive claims are also filed through the same portal.
Sectors
- Health Lifesciences
- Pharmaceuticals
- Pli Scheme
- Manufacturing
- Medical Devices
- Drug Production
- Incentives
- Industry Growth
Details last verified on 12 November 2026. Source: the issuer's published information.